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I. INTRODUCTION
The 2017 Amended Sectoral Annex to the 1998 US-EU Mutual
Recognition Agreement (“2017 Amended US-EU MRA”) became
effective in November 2017, bridging a transatlantic regulatory gap
between the United States (“US”) and the European Union (“EU”).1
Although the Mutual Recognition Agreement (“MRA”) applies
specifically to manufacturing facility inspections,2 it is a giant leap
toward international harmonization of regulatory standards.
This Note will first explore how the Food and Drug Administration
(“FDA”) came into its regulatory authority in the United States.3 The
current drug approval processes will be summarized with a focus on
biological products and their link to manufacturing regulations.4 Next,
1. Press Release, EMA, EU-US Mutual Recognition of Inspections of Medicines
Manufacturers
Enters
Operational
Phase
(Oct.
31,
2017),
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/10/WC50023
7909.pdf [hereinafter EU-US Mutual Recognition of Inspections].
2. Id.
3. See infra Part II.A.
4. See infra Part II.B.
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this Note will take a comparative look at the European Medicines
Agency (“EMA”) and their processes for drug market approval.5 Then,
the 2017 Amended US-EU MRA and its implications will be examined.6
Establishing the regulatory framework for drug approval will give
context to the conclusion that the US’s biosimilar approval processes is
lagging. Biosimilar approval could be streamlined if the FDA utilizes
the lessened burden on manufacturing regulation created by the 2017
Amended US-EU MRA. Working towards a similarly structured mutual
recognition scheme for biosimilar products is a viable solution for the
lagging US biosimilar market.
II. THE REGULATORY FRAMEWORK FOR DRUG APPROVALS
A. Milestones that Empowered the FDA’s Regulatory Role
In response to consumer-protection concerns, Congress passed the
Pure Food and Drugs Act in 1906 which created the FDA.7 At that time,
there was no requirement for regulatory approval of any information
before marketing. 8 The only requirement was for drugs to meet
standards of strength and purity, enforced by the Bureau of Chemistry in
the Department of Agriculture.9 The government had the burden of
proof for showing that a drug’s label was false and misleading to take a
product off the market.10
In U.S. v. Johnson, the Supreme Court in 1911 ruled that “packages
and bottles of medicine bearing labels that stated or implied that the
contents were effective in curing cancer” were not misbranded within
the meaning of Section 2 of the Food and Drugs Act, even with “the
defendant well knowing that such representations were false.”11 This
was because the Bureau of Chemistry of the Department of Agriculture12
only determined whether the ingredients of a product were accurately
represented.13 They had no power to ascertain a product’s medical

5. See infra Part II.C.
6. See infra Part III.
7. U.S. FDA, ABOUT FDA, https://www.fda.gov/AboutFDA/WhatWeDo/History/ (last
updated Sept. 29, 2017).
8. MICHELLE MEADOWS, U.S. FDA, PROMOTING SAFE AND EFFECTIVE DRUGS FOR
100 YEARS,
https://www.fda.gov/downloads/AboutFDA/WhatWeDo/History/FOrgsHistory/CDER/UC
M586463.pdf (last updated June 18, 2009)
9. Id.
10. Id.
11. U.S. v. Johnson, 221 U.S. 488 (1911).
12. The Bureau of Chemistry of the Department of Agriculture acted as a proto-FDA
before the FDA was established. See MEADOWS, supra note 8.
13. Johnson, 221 U.S. at 498.
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effects.14 To overcome this hurdle, Congress enacted the Sherley
Amendment in 1912 to prohibit labeling medicines with false
therapeutic claims intended to defraud purchasers.15 However, the
government still needed to prove an intent to defraud, which limited
enforcement power.16 Finally, Congress passed the Federal Food, Drug,
and Cosmetic Act (“FDCA”) of 1938.17
Under the FDCA,
manufacturers now had to demonstrate their drug’s safety in their market
approval application to the FDA.18
Perhaps the most prominent event that effected change in
regulatory enforcement was the thalidomide tragedy of the early 1960s.
According to Max Sherman and Steven Strauss, “[n]o drug has done, or
is likely to do, more toward the strengthening of existing drug laws in
various countries and toward the creation of drug laws in others that
lacked such legislation before the appearance of this drug in the
marketplace.”19 Thalidomide was a widely used sleeping tablet in
Europe.20 It was also used to treat nausea associated with pregnancy.21
However, after widespread use adverse events started to trickle in,
including “tingling hands, sensory disturbances, and later, motor
disturbances and atrophy of the thumb.”22 These adverse events
attracted the attention of Dr. Frances Kelsey, a physician and
pharmacologist at the FDA.23 She was concerned about a drug’s effect
on pregnancy due to her work with quinine, an anti-malarial drug with
teratogenic effects.24 Because she had observed quinine’s adverse
effects, she requested more data to show that using thalidomide was safe
during pregnancy.25 Her diligence helped America avert a thalidomideinduced birth defect crisis. Across Europe, an alarming number of
babies were being born with congenital birth defects.26 Unfortunately,
it took years and widespread use to establish the relatedness between
14. Id.
15. MEADOWS, supra note 8.
16. Id.
17. Id.
18. Id.
19. Max Sherman & Steven Strauss, Thalidomide: A Twenty-Five Year Perspective, 31
FOOD DRUG COSM. L.J. 458 (1986).
20. Id. at 460.
21. Id.
22. Id. at 460 (citing Helen B. Taussig, A Study of the German Outbreak of Phocomelia,
180 (13) JAMA 1106 (1962)).
23. Sherman, supra note 19, at 461.
24. The use of teratogen indicates that a drug has the capacity under certain exposure
conditions to produce abnormal development in an embryo or fetus. U.S. FDA, REVIEWER
GUIDANCE: EVALUATING THE RISKS OF DRUG EXPOSURE IN HUMAN PREGNANCIES (Apr.
2005), https://www.fda.gov/downloads/Drugs/Guidances/ucm071645.pdf.
25. Sherman, supra note 19, at 461.
26. Id. at 463.

2019]

MUTUAL RECOGNITION OF BIOSIMILARS

207

thalidomide and congenital birth defects. Soon, the thalidomide story
broke in the US and spurred public discourse on drugs and drug
controls.27
Even though it was not approved for use in the US, thalidomide still
found its way to hundreds of pregnant women.28 The need for stronger
enforcement of FDA regulations resulted in the 1962 Kefauver-Harris
Drug Amendments to the Federal FDCA.29 The Investigational New
Drug (“IND”) process was born, enacting procedural requirements
during clinical investigation.30 Market approval from the FDA was now
a requirement.31 Manufacturers now had to prove safety and substantial
effectiveness for a product’s intended use through well-controlled
studies.32 Good manufacturing practices were required and enforced
through inspection.33 Adverse events were required to be reported.34
Further, ethical considerations were implemented: study subjects were
required to give informed consent, review boards approved protocols,
and ethics committees monitored the risk-benefit of a patient’s
participation in a trial.35
Today, the FDA is the global gold standard for rigorous evaluation
of safety, quality, and effectiveness before market approval. 36 The
FDCA37 authorizes the FDA to inspect products already on the market.38
The FDA also regulates manufacturing practices and evaluates new
drugs, medical devices and food additives for safety and effectiveness
before products are marketed to the public.39 If a product is determined
to be unsafe or not FDCA-compliant, the FDA has the power to recall or
seize products.40 In addition, the FDA issues standards for product

27. Id.
28. Id.
29. MEADOWS, supra note 8.
30. Sherman, supra note 19, at 463-64.
31. MEADOWS, supra note 8; see also 21 U.S.C. § 355(a) (West 2018) (requiring
approval of an application for a new drug before introducing it into interstate commerce).
32. MEADOWS, supra note 8.
33. 21 U.S.C. § 355(n)(3) (West 2018).
34. 21 U.S.C. § 355(k)(3)(C) (requiring the establishment and maintenance of
procedures for reporting data on serious adverse drug experiences).
35. U.S. FDA, INSTITUTIONAL REVIEW BOARDS FREQUENTLY ASKED QUESTIONS,
https://www.fda.gov/RegulatoryInformation/Guidances/ucm126420.htm (last visited Mar.
29, 2018) [hereinafter INSTITUTIONAL REVIEW BOARDS FAQS].
36. MEADOWS, supra note 8.
37. 21 U.S.C. §§ 301-399 (West 2018). Food, Drug and Cosmetic Act (FDCA), Practical
Law Glossary Item 7-503-3134.
38. 21 U.S.C. § 341 (West 2018); 21 U.S.C. § 374(a)(1) (West 2018).
39. 21 U.S.C. § 355(a); 21 U.S.C. § 348(b) (West 2018).
40. 21 U.S.C. § 334(a)-(b); 21 U.S.C. § 350l(a)-(b) (West 2018); 21 U.S.C. § 360h(e)
(West 2018).
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labeling and other marketing communications, such as side effects and
drug interactions that must be listed on pharmaceutical labels.41
B. How Do Drugs Get Approved?
Market approval of novel medical therapies weighs two important
interests.42 First, the product must be safe and effective.43 Second, a
thorough but expedient review process determines whether to grant
public access to innovative therapies.44
A drug manufacturer, also known as the sponsor,45 first identifies a
medicinal product for commercialization. If the product is a biologic
that is also a “drug,” the biologic is subject to additional provisions of
the FDCA.46 A “biologic,” or “biological product,” refers to a virus,
therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or
derivative, allergenic product, or protein applicable to the prevention,
treatment, or cure of a disease or condition of human beings.47
During preclinical development, the sponsor assesses the proposed
product’s pharmacological activity and determines if it is reasonably
safe for human use.48 If so, the sponsor files an Investigational New
Drug (“IND”) application.49 Clinical trials are then initiated to prove a
proposed drug’s safety and efficacy.50 Scientifically robust studies
produce clinical data that are used to support a drug manufacturer’s
application to market the drug, known as a New Drug Application
(“NDA”).51 The NDA also contains proposed labeling, safety updates,
drug abuse information, patent information, data from studies outside of
the US, institutional review board compliance information, and
directions for use. 52

41. See 21 U.S.C. §§ 343-343-3, 352, 360 (West 2018).
42. Gail A. Van Norman, Drugs and Devices: Comparison of European and U.S.
Approval Processes, 1 JACC: BASIC TO TRANSLATIONAL SCI. 399, 400 (2016).
43. Id.
44. Id.
45. “Sponsor means a person who takes responsibility for and initiates a clinical
investigation.” 21 C.F.R. § 312.3 (2017).
46. 42 U.S.C. § 262(j) (2017).
47. 42 U.S.C. § 262(i)(1).
48. U.S.
FDA,
INVESTIGATIONAL
NEW
DRUG
(IND)
APPLICATION,
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm
(last
updated Oct. 5, 2017).
49. U.S. FDA, STEP 3: CLINICAL RESEARCH,
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm (last updated Jan. 4,
2018).
50. Id.
51. Id.
52. Id.
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In the case of biologics, the sponsor submits a Biologics License
Application (“BLA”).53 The BLA must include a full description of
manufacturing methods; data establishing stability of the product
through the dating period; sample(s) representative of the product;
summaries of results of tests performed on the lot(s) represented by the
submitted sample(s); and specimens of the labels, enclosures, and
containers.54
An FDA review team reviews preclinical and clinical data
demonstrating a proposed drug’s safety and efficacy for intended use.
After submission, the FDA review team55 categorically evaluates the
data submitted and conducts clinical site inspections to supplement their
review. 56 A decision to grant approval is made within six to ten
months.57
1. IND Requirements
The IND application is necessary to commence clinical studies
because it is the means through which a sponsor obtains an exemption
from the FDA to ship the investigational drug to interstate clinical
investigators.58 At a minimum, an application must include (1) full
reports of investigations that demonstrate a drug’s safety and efficacy in
use, (2) a full list of articles used as components of the drug, (3) a full
statement of the drug’s composition, (4) a description of the methods
used in, the facilities and controls used for, the manufacturing,
processing, and packaging of the drug, (5) samples of the drug and
articles used as components of the drug, and (6) proposed labeling for
the drug.59

53. 21 C.F.R. § 601.2(a) (2017).
54. Id.
55. A review team consists of specialists representing different scientific fields. A
Project Manager coordinates the team’s activities and acts as the primary contact for the
sponsor; a medical officer reviews clinical study information; a statistician interprets clinical
trial designs and data; a pharmacologist reviews preclinical studies; a pharmakineticist
evaluates a drug’s absorption, distribution, metabolism and excretion processes; and a chemist
evaluates a drug’s chemical makeup. STEP 3, supra note 49.
56. U.S.
FDA,
STEP
4:
FDA
DRUG
REVIEW,
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405570.htm (last updated Jan. 4,
2018).
57. Id.
58. INVESTIGATIONAL NEW DRUG (IND) APPLICATION, supra note 48. See also 21
U.S.C. § 355(a) (2017) (“No person shall introduce or deliver for introduction into interstate
commerce any new drug, unless an approval of an application filed…is effective with respect
to such drug.”).
59. 21 U.S.C. § 355(b)(1) (2017).
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2. Proving Safety and Efficacy: Clinical Trials of an
Investigational New Drug
An IND application must submit preclinical data from animal
pharmacology and toxicology studies to demonstrate a drug’s safety and
efficacy.60 It must also provide detailed protocols for proposed clinical
studies.61
The clinical investigation of a previously untested drug is divided
into phases.62 In Phase 0 and 1 trials, a small population of healthy
subjects are dosed with the investigational product.63 This serves to
investigate the pharmacology of the drug in humans, detect side effects
associated with increasing doses, and gain early evidence on
effectiveness.64 These trials establish the product’s safety for human use.
Phase 2 trials are next. Hundreds of patients who are afflicted with the
drug’s proposed indication are given incremental doses of the study
drug.65 This phase will observe the efficacy of the drug for its intended
purpose.66 Finally, Phase 3 trials increase the patient population.67 Up
to thousands of patients are dosed with the investigational product to
demonstrate efficacy while monitoring adverse reactions.68 Afterwards,
a risk-benefit profile is developed to inform physician labelling.69
a. Evaluating Safety by Monitoring Adverse Events
Clinical trial progression is ultimately driven by the adverse events
that emerge after using the drug product. An “adverse event” means any
untoward medical occurrence associated with the use of a drug in
humans, whether or not considered drug-related.70 “Serious adverse
events” refer specifically to adverse events with outcomes such as death,
a life-threatening event, inpatient hospitalization or prolongation of
existing hospitalization, a persistent or significant disability, congenital

60. INVESTIGATIONAL NEW DRUG (IND) APPLICATION, supra note 48.
61. U.S. FDA, GUIDANCE FOR INDUSTRY: CONTENT AND FORMAT OF
INVESTIGATIONAL NEW DRUG APPLICATIONS (INDS) FOR PHASE 1 STUDIES OF DRUGS,
INCLUDING WELL-CHARACTERIZED, THERAPEUTIC, BIOTECHNOLOGY-DERIVED PRODUCTS
(Nov. 1995), https://www.fda.gov/downloads/Drugs/. . ./Guidances/ucm074980.pdf.
62. 21 C.F.R. § 312.21 (2017).
63. AM. CANCER SOC’Y, WHAT ARE THE PHASES OF CLINICAL TRIALS?,
https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-needto-know/phases-of-clinical-trials.html (last updated Feb. 7, 2017).
64. 21 C.F.R. § 312.21(a)(1).
65. See 21 C.F.R. §312.21(b).
66. 21 C.F.R. § 312.21(b).
67. See 21 C.F.R. §312.21(c).
68. Id.
69. Id.
70. 21 C.F.R. § 312.32(a).
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birth defects, or an important medical event.71 A serious adverse event
is reportable to the FDA in an “IND safety report” when there is a
reasonable possibility of a causal relationship between the drug and the
adverse event and if the event is unexpected.72 “Expectedness” refers to
whether or not the event is listed in the investigator brochure as an
identified risk described in the general investigational plan.73 Such
reports must also be made known to participating investigators to whom
the sponsor is providing the study drug.74
Standardizing causality assessments is trickier. Although causality
is ultimately a clinical judgment, there are instances that allude to
relatedness: (1) a single occurrence of an event that is uncommon and
known to be strongly associated with drug exposure;75 (2) one or more
occurrences of an event that is not commonly associated with drug
exposure, but is other uncommon in the population exposed to the drug;76
(3) an aggregate analysis of specific events observed that indicate an
event may be occurring more frequently in the drug treatment group than
a control group.77
The sponsor company and the clinical site monitor the progress of
each patient enrolled in the clinical trial. 78 They do this by selecting
qualified investigators, providing them with the information needed to
properly conduct the investigative study, monitor the study’s progress,
and ensure that the FDA and all participating investigators are promptly
informed of significant new adverse events or risk.79 Principal
investigators lead clinical sites and review adverse events occurring in
the clinical trial.80 Ultimately, the principal investigator assesses the
investigational product’s causality to the adverse event. An Institutional
Review Board (“IRB”) reviews clinical protocols before a trial begins,
monitors the progress, maintains records, and assure clinical testing
meets ethical standards.81 A Data Monitoring Committee (“DMC”) will
review patient data to ensure that a drug is demonstrating safety and

71.
72.
73.
74.
75.
76.
77.
78.

Id.
21 C.F.R. § 312.32 (c)(1)(i) (2017).
See 21 C.F.R. §312.21(a).
21 C.F.R. § 312.32(c)(1).
21 C.F.R. § 312.32(c)(1)(i)(A).
21 C.F.R. § 312.32(c)(1)(i)(B).
21 C.F.R. § 312.32(c)(1)(i)(C).
U.S. FDA, INVESTIGATOR RESPONSIBILITIES — REGULATION AND CLINICAL
TRIALS, (Nov. 13, 2013),
https://www.fda.gov/downloads/training/clinicalinvestigatortrainingcourse/ucm378565.pdf.
79. Id. at 36.
80. Id.
81. INSTITUTIONAL REVIEW BOARDS FAQS, supra note 35.
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efficacy.82 If the patient risk is too high, the trial could be terminated.83
If the drug is not demonstrating efficacy, then it is meaningless to
continue the study and deprive patients the standard of care, if available.
b. Proving Efficacy
For marketing approval, companies must present substantial
evidence that the investigational product has a clinically meaningful
effect.84 Patients participate in clinical studies seeking improved
survival, detectable benefits such as symptom relief, or decreased
chances of developing a disease complication (e.g. stroke).85 To show
efficacy, clinical trials should have an endpoint with a measurable
outcome.86 Objective endpoints include quantitative measurements of
biochemical parameters, survival, disease exacerbation, or important
medical events (e.g. stroke). Subjective measures as endpoints evaluate
outcomes such as symptom scores and quality-of-life evaluations.87
Ideally, the endpoints will prove efficacy by demonstrating a
statistical significance between two treatments or strategies being
compared with respect to the endpoint measure.88
3. Demonstrating Quality and Potency: Manufacturing Practices
The FDA regulates pharmaceutical quality and manufacturing
standards with a series of continuously updated guidance documents
published as the Current Good Manufacturing Practice (“CGMP”)
Standards.89 CGMPs generally outline systems for proper design,
monitoring, and control of manufacturing processes and facilities.90 This
82. U.S. FDA, ESTABLISHMENT AND OPERATION OF CLINICAL TRIAL DATA
MONITORING
COMMITTEES
FOR
CLINICAL
TRIAL
SPONSORS,
https://www.fda.gov/RegulatoryInformation/Guidances/ucm127069.htm (last visited Mar.
29, 2018).
83. Id.
84. Eugene J. Sullivan, U.S FDA, CLINICAL TRIAL ENDPOINTS 3,
https://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM337268.
pdf (last visited Jan. 30, 2018).
85. Id.
86. See Joseph Spahn, Clinical Trial Efficacy: What Does it Really Tell You?, 112 J. OF
ALLERGY & CLINICAL IMMUNOLOGY 102 (2003).
87. Id.
88. See OFF. OF BEHAV. & SOC. SCI. RES., CLINICAL TRIALS: ENDPOINTS,
http://www.esourceresearch.org/eSourceBook/ClinicalTrials/4Endpoints/tabid/200/Default.a
spx (last visited Jan. 30, 2018).
89. See U.S. FDA, PHARMACEUTICAL QUALITY/MANUFACTURING STANDARDS
(CGMP),
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064
971.htm (last updated Oct. 6, 2017).
90. U.S. FDA, FACTS ABOUT THE CURRENT GOOD MANUFACTURING PRACTICES
(CGMPS),
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includes establishing strong quality management systems, obtaining
appropriate quality raw materials, establishing robust operating
procedures, detecting and investigating product quality deviations, and
maintaining reliable testing laboratories.91 Regulation adherence
ensures patient safety. Failure to comply with CGMP regulations results
in “adulterated products” that could be subject to recall—or in cases of
noncompliance with a recall request, an injunction and product seizure.92
Information pertaining to the composition, manufacturing, stability, and
controls used in drug manufacturing is assessed to ensure that the
sponsor can adequately produce and supply consistent batches of the
drug. 93
C. The EMA’s Regulatory Role
The European Medicines Agency (“EMA”) oversees the European
medicines regulatory network through a collaboration between the
European Commission (EC) and regulatory authorities in European
Economic Area (“EEA”) countries.94 Marketing authorization—that is,
the legal decision to grant, suspend or revoke a marketing authorization
for any medicine—in the EU falls under the purview of the EC.95
Market-authorization holders (i.e. biopharmaceutical companies) submit
single market-authorization applications for the EMA to evaluate.96 In
this sense, the EMA’s centralized authorization process is similar in
function to the FDA, which oversees all drug approvals in the United
States. Under the centralized process, the EMA carries out scientific
assessment of the application and recommends approval.97
Authorization decisions are made in the interest of public health “on the
basis of objective scientific criteria of quality, safety and efficacy of the
medicinal product concerned, to the exclusion of economic and other

https://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/ucm169105.htm
(last updated Oct. 6, 2017).
91. Id.
92. Id.
93. Id.
94. EUROPEAN
MED.
AGENCY,
HISTORY
OF
THE
EMA,
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000
628.jsp (last visited Jan. 20, 2018).
95. EUROPEAN
MED.
AGENCY,
WHAT
WE
DO,
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000
091.jsp (last visited Jan. 20, 2018).
96. See
EUROPEAN
MED.
AGENCY,
LEGAL
FRAMEWORK,
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000
127.jsp (last visited Jan. 20, 2018).
97. WHAT WE DO, supra note 95.
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considerations.”98 “Every member state of the EU is represented on the
EMA committee for Medicinal Products.”99
The centralized plan aimed to reduce the cost for drug companies
to obtain approvals and eliminate protectionist tendencies of member
nations that would otherwise favor domestic products.100 Moreover, the
EMA and Member States cooperate and share expertise in assessing new
medicines and safety information through reviewing reported side
effects, overseeing of clinical trials, and conducting of manufacturing
inspections.101 Functionally, the EMA is a conglomerate of its Member
States’ regulatory authorities. As such, the EMA has several routes to
drug approval beyond the centralized procedure.
1. EU Authorization through National Authorization
Of course, regulatory authorities of EU Member States can also
authorize products nationally. The local regulatory authority would be
responsible for authorizing medicines not passing through the
centralized procedure.102 Here, the national regulatory authority would
be responsible for verifying that manufacturers and importers of
medicinal products coming from outside the EU follow EU-established
manufacturing standards.103
2. EU Authorization through Mutual Recognition
The EMA is perhaps the “best-established example of regulatory
cooperation between medicines authorities.”104 Within the EMA
network, Directive 2004/27/EC outlines a mutual recognition procedure

98. Regulation (EC) 726/2004 of the European Parliament and of the Council: Laying
Down Community Procedures for the Authorisation and Supervision of Medicinal Products
for Human and Veterinary Use and Establishing a European Medicines Agency, 2004 O.J. (L
136), 1, 4 https://ec.europa.eu/health//sites/health/files/files/eudralex/vol1/reg_2004_726/reg_2004_726_en.pdf [hereinafter Regulation 726/2004/EC].
99. Norman, supra note 42.
100. Id.
101. EUROPEAN MED. AGENCY, THE EUROPEAN REGULATORY SYSTEM FOR MEDICINES:
A CONSISTENT APPROACH TO MEDICINES REGULATION ACROSS THE EUROPEAN UNION,
http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2014/08/WC500171674.p
df (last visited Jan. 20, 2018).
102. EUROPEAN MED. AGENCY, NATIONAL COMPETENT AUTHORITIES (HUMAN),
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_00
0155.jsp&mid=WC0b01ac0580036d63 (last visited Jan. 20, 2018).
103. Directive 2001/83/EC of the European Parliament and of the Council of 6 November
2001 on the Community Code Relating to Medicinal Products for Human Use, art. 20, 2001
O.J. (L 311).
104. Riccardo Luigetti, Peter Bachmann, Emer Cooke & Tomas Salmonson,
Collaboration, Not Competition: Developing New Reliance Models, 30 WHO DRUG INFO.
558, 559 (2016).
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for EU market authorization.105 Medicines that already received
authorization in one EEA Member State may apply for mutual
recognition in other Member States.106 The applicant will request one
Member State to be the “reference Member State” to evaluate the
medicine and decide whether to grant authorization.107 The other
Member States, the “concerned Member States,” must adopt a decision
that conforms with the approved assessment report from the reference
Member State, the summary of product characteristics, and the labelling
and package leaflet as approved.108
3. EU Authorization through the Decentralized Procedure
Directive 2004/27/EC outlines the decentralized procedure for
marketing authorization.109 Though very similar to the mutual
recognition procedure, the decentralized procedure is enacted for
medicines that have not previously received marketing authorization.110
Like the mutual recognition procedure, it relies on national authorization
in one Member State to obtain mutual recognition.111 Under the
decentralized procedure, identical dossiers are submitted to all Member
States where marketing authorization is sought.112 Effectively, this
process joins concerned Member States at an earlier stage of evaluation
to minimize disagreements when adopting mutual recognition of the
novel therapy.
4. Timeline Efficiency Compared to the FDA
The issue is then whether shared expertise framework of the EMA
approval process creates any efficiencies. Between 2011 and 2015, the
FDA approved 170 new therapeutic agents compared to the EMA which
approved 144.113 The therapeutic areas of the approvals were similar in
the two agencies, although the FDA approved more orphan drugs than
by the EMA (43.5% vs. 25.0% of the approved agents).114 The total

105.
106.
107.
108.
109.
110.

See Directive 2004/27/EC, art. 28, 2004 O.J. (L 136/44).
Id. at art. 28.
Id.
Id.
See id. at arts. 27-32.
EUROPEAN COMM’N, AUTHORISATION PROCEDURES — THE DECENTRALISED
PROCEDURE, https://ec.europa.eu/health/authorisation-procedures-decentralised_en (last
visited Jan. 20, 2018).
111. Id.
112. Directive 2004/27/EC, art. 28, 2004 O.J. (L 136/44).
113. Nicholas S. Downing, Audrey D. Zhang & Joseph S. Ross, Regulatory Review of
New Therapeutic Agents — FDA versus EMA, 2011-2015, 376 NEW ENG. J. MED. 1386
(2017).
114. Id.
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review times did vary based on therapeutic areas; the FDA had shorter
times for cancer and hematologic disease treatments as well as orphan
drugs.115 However, on average FDA review periods were sixty days
shorter than those by the EMA.116
D. The Pathway for Approval of Biosimilars in the US and EU
A “biosimilar” is a biological product that is highly similar to a
reference product except for minor differences in clinically inactive
components.117 In the US, biologic product licensing and regulation is
governed by the Public Health Service Act (“PHSA”).118 The Biologics
Price Competition and Innovation Act (“BPCIA”) of 2009 passed as part
of the Affordable Care Act in 2010.119 The BPCIA created an
abbreviated pathway for biosimilar or interchangeable products
licensing by relying on the safety and efficacy data in an FDA-approved
reference product.120 Essentially, BPCIA enables a biosimilar biological
product to be licensed based on less than a full complement of productspecific preclinical and clinical data.121
Genetically engineering cells to produce biologics is a complex
process that drives up the costs of biological products.122 BPCIA’s aim
was to increase access to treatment and to lower health care costs.123 The
EU had implemented a similar abbreviated approval pathway for
biosimilars in 2005.124 Greater availability of biosimilar products,
especially in low-income EU countries, influenced national drug

115. Id.
116. Id.
117. 42 U.S.C. § 262(i)(2)(A).
118. Biological products are approved and regulated under Section 351 of the Public
Health Service Act, which is codified at 42 U.S.C. § 262.
119. Darryl Woo, Erin A. Thomson, Janice Ta & Wendy Wang, Amgen v Sandoz:
Marketing Exclusivity Under the BPCIA, LIFE SCI. INTELL. PROP. REV. (2016).
120. Id.
121. LEAH CHRISTL, U.S. FDA, OVERVIEW OF THE REGULATORY FRAMEWORK AND
FDA’S GUIDANCE THE DEVELOPMENT AND APPROVAL OF BIOSIMILAR PRODUCTS IN THE US
4,
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
OncologicDrugsAdvisoryCommittee/UCM561565.pdf (last visited Jan. 30, 2018).
122. Practical Law Intellectual Property & Technology, What You Need to Know About
the BPCIA, Practical Law Legal Update 5-590-4543 (Dec. 2, 2014) (West).
123. Id.
124. Martin Schiestl, Markus Zabransky, & Fritz Sörgel, Ten Years of Biosimilars in
Europe: Development and Evolution of the Regulatory Pathways, 11 DRUG DESIGN, DEV. &
THERAPY 1509 (2017).

2019]

MUTUAL RECOGNITION OF BIOSIMILARS

217

reimbursement systems.125 This resulted in increased access to effective
treatment because of reduced costs to patients.126
The EU pathway for the approval of biosimilars is comparable to
the FDA’s process. The Committee for Medicinal Products for Human
Use (“CHMP”) under the EMA issues guidelines for the biosimilar
regulatory framework.127 The CHMP provides initial assessments for
marketing authorization of new medicines that are ultimately approved
centrally by the EMA.128
1. Demonstrating Quality of the Proposed Biosimilar
Biosimilars, like all medicinal products approved in the EU and US,
must demonstrate pharmaceutical quality.129 But unlike traditional
pharmaceuticals and their respective generics, biologics are not able to
be manufactured as perfect equivalents.130 Traditional pharmaceutical
drugs are chemically synthesized small molecules.131 In contrast,
biologics are complex macromolecular structures consisting of
proteins.132 Biologics have inherent variability because they are
produced via living cells, which can modify protein structure based on
its growth environment.133 However, biologics product quality is not
affected so long as the critical attributes of the biologic’s structure is
carefully monitored and retained.134

125. The reimbursement criteria for biosimilars were similar to those for other generic
products in that the pricing policies for biosimilar medicines was set in relation to the price of
the originator. See Pawl Kawalec et al., Pricing and Reimbursement of Biosimilars in Central
and Eastern European Countries, 8 FRONTIERS IN PHARMACOLOGY (June 2017),
https://www.frontiersin.org/articles/10.3389/fphar.2017.00288/full.
126. The high price of original drugs limits access to treatment, especially in low-income
Central and Eastern European countries. Id.
127. The legal basis for similar biological applications can be found in Regulation
726/2004/EC, O.J. (L 136/1), art. 6.
128. EUROPEAN MED. AGENCY, GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
PRODUCTS, CHMP/437/04 (Oct. 30, 2005).
129. EUROPEAN MED. AGENCY, BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR
HEALTHCARE
PROFESSIONALS
10,
http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.p
df (last visited Jan. 30, 2018).
130. U.S.
FDA,
BIOSIMILAR
AND
INTERCHANGEABLE
PRODUCTS,
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm#
biological (last updated Oct. 23, 2017).
131. BIOTECHNOLOGY INNOVATION ORG., HOW DO DRUGS AND BIOLOGICS DIFFER?,
https://www.bio.org/articles/how-do-drugs-and-biologics-differ (last visited Apr. 28, 2018).
132. Id.
133. Arnold G. Vulto & Orlando A. Jaquez, The Process Defines the Product: What
Really Matters in Biosimilar Design and Production?, 56 RHEUMATOLOGY iv14 (Aug. 30,
2017).
134. Id.
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The FDA grants licensure for biosimilars in a process analogous to
the aforementioned NDA process.135 In the Biologics License
Application (“BLA”), the proposed biosimilar must include analytical
studies demonstrating that the product is highly similar to the reference
product, minus inactive components.136 Animal studies are included to
assess toxicity.137 Clinical studies test safety, purity, and potency of the
product for its intended use.138 Furthermore, the route of administration,
dosage form, and strength of the biosimilar must be same as those of the
reference product.139 Finally, the manufacturing practices used to
produce the biosimilar must meet standards to ensure a safe, pure, and
potent product.140
The FDA, through its Center for Biologics Evaluation and Research
(“CBER”),141 “inspects manufacturing plants before it approves
products, and thereafter, on a regular basis” to ensure that biological
products are confirming to laws and regulations.142 Companies must
report to the CBER within forty-five days of awareness of any biological
product deviations from good manufacturing practice that may affect the
safety, purity, or potency of a distributed product.143 This includes
testing, processing, packing, labeling, or storage, or with the holding or
distribution of a licensed biological product. 144 Regulatory approvals of
biologics are more demanding than regulatory approvals of general drug
products. More studies are required to show product quality because of
the variability expected in manufacturing biologic products.
2. Comparative Studies to Establish High Similarity and
Interchangeability
A biosimilar product must have no clinically meaningful
differences between the reference biologic product in terms of safety,
purity, and potency of the product.145 To demonstrate that the active
substance of the proposed biosimilar is highly similar to the reference
135. The Food and Drug Administration Modernization Act of 1997 created uniformity
between the NDA and BLA approval processes.
136. 42 U.S.C. § 262(k)(2)(A).
137. Id.
138. Id.
139. Id.
140. Id.
141. U.S. FDA, CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER)
RESPONSIBILITIES QUESTIONS AND ANSWERS,
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBE
R/ucm133072.htm (last updated Aug. 5, 2015).
142. Id.
143. 21 C.F.R. § 606.171 (2017).
144. Id.
145. 42 U.S.C. § 262(i)(2)(B).
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medicine, comprehensive comparative studies are first conducted with
the reference medicine.146 Extensive biochemical and biophysical
analytical methods are used to confirm the primary structure and protein
modification that may result from protein biosynthesis.147 If the
proposed biosimilar is structurally comparable to the reference
medicine, the positive benefit-risk profile of the reference medicine is
conferred upon the biosimilar.148 The biosimilar can then quickly move
through the approval process by relying on the efficacy and safety data
of the reference biologic.149
The next step is to conduct comparative clinical studies in human
subjects. “The aim of studies in humans is not to demonstrate safety and
efficacy in patients, as these have already been established for the
reference medicine.”150 Rather, the studies ensure that the biosimilar’s
pharmacokinetics and pharmacodynamics (describing exposureresponse relationships) conforms with the reference product. 151
“Interchangeable products” are biosimilars that need to meet
additional requirements. 152 As its name suggests, an interchangeable
product should be substitutable for the reference product without
prescriber involvement; switching back and forth between an
interchangeable product and a reference product should not impact the
safety nor efficacy.153 For interchangeable products, the FDA requires a
transition study to show that there are no increases in safety events
between a patient cohort that stays on the reference product compared to
the cohort that switches to the biosimilar. 154
Though the
interchangeability pathway is not required by the FDA,
interchangeability is a prerequisite for automatic substitution at the

146. BIOSIMILAR AND INTERCHANGEABLE PRODUCTS, supra note 130.
147. Elizabeth Hyland et al., Comparison of the Pharmacokinetics, Safety, and
Immunogenicity of MSB11022, a Biosimilar of Adalimumab, with Humira® in Healthy
Subjects, 82 BRITISH J. OF CLINICAL PHARMACOLOGY 983 (2016).
148. Id.
149. A manufacturer need only show that its biosimilar product is highly similar and has
no clinically meaningful differences from the approved reference product (which already has
a full profile nonclinical and clinical data). Patient access is much quicker because redundant
clinical trials are not necessary. U.S. FDA, BIOSIMILAR DEVELOPMENT, REVIEW, AND
APPROVAL,
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapprove
d/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580429.htm#process
(last updated Oct. 23, 2017).
150. BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR HEALTHCARE PROFESSIONALS,
supra note 129.
151. CHRISTL, supra note 121.
152. BIOSIMILAR AND INTERCHANGEABLE PRODUCTS, supra note 130.
153. Id.
154. See id.
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pharmacy level.155 Pharmacy level interchangeability allows drug
substitution without input from a doctor. Pharmacy-level substitution is
already the case for traditional generics.156 To save costs, insurance
companies could exclusively cover interchangeable biosimilars when
one is available in lieu of paying full price for the original biologic.157
E. A New Drug is Approved: The Post-Market Landscape
Post-marketing studies allow monitoring of known risks.
Furthermore, because the drug is now available to a larger number of
patients treated over a longer period, detection of rare adverse drug
reactions may be made from the aggregate data. For example, the
congenital birth defects linked to thalidomide were not discovered until
after mass-market use.158
Experiences which are both “serious”159 and “unexpected”160 must
be reported to the FDA within fifteen calendar days.161 All other adverse
drug experiences for NDA-approved products are compiled into periodic
reports for the FDA quarterly or annually, depending on how long the
drug has been approved.162 Additionally, manufacturers proactively
seek information about their products from a variety of sources:
scientific
literature,
commercial
marketing
experience,
epidemiological/surveillance studies.163
Failure to establish and
maintain records and make reports may result in the FDA withdrawing
approval which would prohibit continued marketing of the drug.164
Since comprehensive clinical testing is often not required, postmarket safety monitoring is particularly important for biosimilars
because of the limited clinical data available at the time of approval.165

155. Id.
156. Lauren F. Friedman, An Innovation that Could Transform the Drug Industry Faces
a Major Hurdle, BUS. INSIDER (Apr. 29, 2015), http://www.businessinsider.com/biosimilarsbioequivalence-and-interchangeability-2015-4.
157. Id.
158. As discussed supra Part II.A, thalidomide was widely used across Europe before an
alarming number of congenital birth defects were associated with the drug.
159. See 21 C.F.R. § 312.32(a).
160. Id.
161. 21 C.F.R. § 314.80(c)(1)(i) (2017).
162. 21 C.F.R. § 314.80(c)(2)(i).
163. 21 C.F.R. § 314.80(b).
164. 21 C.F.R. § 314.80(k).
165. Donna M. Gitter, Informed by the European Union Experience: What the United
States Can Anticipate and Learn from the European Union’s Regulatory Approach to
Biosimilars, 41 SETON HALL L. REV. 559, 582-83 (2011).
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F. US-EU Harmonization: A Mutual Recognition Agreement
A Mutual Recognition Agreement (“MRA”) is an agreement
between two or more countries to recognize a specific process or
procedure in the other country.166 Effectively, MRAs are trade
agreements that encourage greater international harmonization of
compliance standards and consumer protection.167 MRAs facilitate
market access in an age where the manufacture and distribution of
modern medicines is increasingly globalized168 by strengthening use of
each agency’s drug inspection expertise and resources, resulting in
“greater efficiencies for both regulatory systems and provide a more
practical means to oversee the large number of drug manufacturing
facilities outside of the US and EU.” 169
In 1998, the US and EU entered into a MRA with provisions
concerning current Good Manufacturing Practices, which were never
fully implemented.170 For the MRA to operate, the US and EU needed
“reassurance that the GMP inspectorates on both sides have the
capability, capacity and procedures in place to supervise manufacturers
of medicines at an equivalent level.”171 As such, since 2014, teams from
EU national authorities,172 the European Commission, EMA, and the
FDA have audited and assessed the respective supervisory systems.173
Such assessments included internal audits of each country’s processes,
workforce skills, compliance with local laws and guidelines.174
Effective November 2017, US and European regulators agreed on
mutual recognition of inspections of medicines conducted in their
respective territories.175 This MRA would allow the US and EU to rely
on each other’s good manufacturing practices system, share information
166. U.S. FDA, FREQUENTLY ASKED QUESTIONS / THE MUTUAL RECOGNITION
AGREEMENT
1
(July
2017),
https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOpera
tionsandPolicy/UCM544394.pdf [hereinafter FAQ / THE MUTUAL RECOGNITION
AGREEMENT].
167. EUROPEAN
MED.
AGENCY,
MUTUAL
RECOGNITION
AGREEMENTS,
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_00
1843.jsp&mid=WC0b01ac058005f8ac (last visited Jan. 30, 2018) [hereinafter MUTUAL
RECOGNITION AGREEMENTS].
168. Luigetti et al., supra note 104.
169. FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166.
170. Id.
171. EU-US MUTUAL RECOGNITION OF INSPECTIONS, supra note 1.
172. For a full list of each Member State’s national regulatory authority, see EUROPEAN
MED.
AGENCY,
NATIONAL
COMPETENT
AUTHORITIES
(HUMAN),
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_00
0155.jsp (last visited Jan. 30, 2018).
173. EU-US MUTUAL RECOGNITION OF INSPECTIONS, supra note 1.
174. FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166.
175. EU-US MUTUAL RECOGNITION OF INSPECTIONS, supra note 1.
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on inspections and quality defects, and waive batch testing of products
on import.176 “The 2017 Amended Sectoral Annex to the 1998 US-EU
MRA allows the FDA and the EU inspectorates to use inspection reports
and other related information obtained during drug manufacturing
facility inspections, whether conducted by an EU inspectorate or by the
FDA, to help determine whether a facility is manufacturing high quality
drugs.”177
Of note, the MRA stipulates that the FDA will conduct an
individual assessment of each EU Member State’s regulatory authority
before the MRA is effective.178 Also, the FDA or EU reserve the ability
to require further inspections as deemed necessary.179
With the enactment of the 2017 Amended US-EU MRA,
duplicative inspections should be the exception.180 This will allow the
FDA and EMA to allocate resources toward addressing higher public
health risks thereby benefiting patient care. 181

176.
177.
178.
179.
180.
181.

MUTUAL RECOGNITION AGREEMENTS, supra note 167.
FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166.
Id.
Id.
Id.
Id.
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III. IF BPCIA WAS SUPPOSED TO SPEED THINGS UP, WHY IS
BIOSIMILAR APPROVAL STILL SLOW?
A. The United States is Trailing the European Union in Biosimilar
Approvals
The first FDA-licensed biosimilar was Zarxio, approved in 2015.182
In 2016, the FDA only licensed three new biosimilars.183 However, 2017
was a banner year for biosimilar approvals by the FDA. The FDA
approved five biosimilars in 2017 for a total of nine approved overall.184
This update may be credited to the FDA’s January 2017 release of a
long-awaited draft guidance on interchangeability considerations.185
Previously, the FDA was providing one-on-one advice to sponsors about
data expected to demonstrate interchangeability.186 The draft guidance,
“Considerations in Demonstrating Interchangeability With a Reference
Product,” clarifies expectations.187 However, the guidance document
does recommend that the comparator used in switching studies be a USlicensed reference product instead of a foreign-approved product. 188
Although this guidance is specifically for interchangeable products, it
still provides insight into the FDA’s standards for biosimilar approval.
The US trails behind the EMA’s fifty-four approved biosimilars,
which represent sixteen unique biologics.189
The chart below

182. Sue Sutter, Biosimilars in 2017: Crowded US FDA Review Queue, Key Legal
Decisions,
PINK
SHEET
PHARMA
INTELL.
(Jan.
24,
2017),
https://pink.pharmaintelligence.informa.com/PS119882/Biosimilars-In-2017-Crowded-USFDA-Review-Queue-Key-Legal-Decisions;
U.S.
FDA,
B IOSIMILAR
PRODUCT
INFORMATION,
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580432.htm.
183. Id.
184. Jacob F. Siegel & Irena Royzman, US Biosimilar Approvals Soar in 2017,
BIOLOGICS BLOG (Dec. 18, 2017), https://www.biologicsblog.com/us-biosimilar-approvalssoar-in-2017.
185. The draft guidance formally lays out FDA expectations for interchangeability. This
has standardized the process which previously relied on one-on-one communications between
the agency and sponsor. Sutter, supra note 182.
186. Sutter, supra note 182.
187. See U.S. FDA, DRAFT GUIDANCE FOR INDUSTRY: CONSIDERATIONS IN
DEMONSTRATING INTERCHANGEABILITY WITH A REFERENCE PRODUCT, (Jan. 2017),
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan
ces/UCM537135.pdf.
188. Id. at 15. See also infra Part V.C for discussion on how this requirement could be
superseded by the EU-US Mutual Agreement.
189. As of Dec. 30, 2018 there are fifty-three approved biosimilars and one approval
pending. See EUROPEAN MED. AGENCY, LIST OF BIOSIMILARS APPROVED BY THE EMA,
http://www.ema.europa.eu/ema/ (select “Search” under “Medicines” tab; then select
“Human” category; then select “Biosimilars” under medicine type) (last visited Dec. 30, 2018)
[hereinafter LIST OF BIOSIMILARS APPROVED BY THE EMA].
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demonstrates that the EU has a wide breadth of available biosimilars.
For some active substances, the EU has approved multiple biosimilars.
Table 1: Number of Biosimilars Approved in the EMA v. FDA
Active
Substance

Brand Name190

# Approved
by EMA191

# Approved
by FDA192

adalimumab

Humira®

8

3

bevacizumab

Avastin®

1

1

enoxaparin
sodium

Lovenox®

2

0

epoetin alfa

Epogen®

3

1

epoetin zeta

Retacrit®

2

0

etanercept

Enbrel®

2

1

filgrastim

Neupogen®

7

2

follitropin alfa

Gonal-f®

2

0

infliximab

Remicade®

4

3

insulin
glargine

Lantus®

3

0

insulin lispro

Humalog®

1

0

pegfilgrastim

Neulasta®

5

2

rituximab

Rituxan®

6

1

somatropin

Norditropin®

1

0

teriparatide

Forteo®

2

0

trastuzumab

Herceptin®

4

2

TOTAL

53

16

The FDA and EMA have nine approved biosimilars in common. 193
Three biosimilars are exclusively approved in the US; Ixifi (infliximab),
190. To identify brand name from active substance, see Drugs A-Z List, RXLIST,
https://www.rxlist.com/drugs/alpha_a.htm (last visited Nov. 3, 2018).
191. LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189.
192. U.S.
FDA,
BIOSIMILAR
PRODUCT
INFORMATION,
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580432.htm.
193. The nine approved biosimilars in common are: Amgevita (adalimumab), Cyltezo
(adalimumab), Hyrimoz (adalimumab), Mvasi (bevacizumab), Retacrit (epoetin alfa), Erelzi
(etanercept), Zarzio (filgrastim), Nivestym (filgrastim), and Inflectra (infliximab)). Compare
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Renflexis (infliximab), and Ogivri (trastuzumab) are not yet approved
by the EMA as of December 2018. However, for each of these, at least
one biosimilar with the same active substance is authorized for sale in
the EU market. Seven active substances approved in the EMA have not
yet been approved by the FDA.
Table 2 below shows that the EMA has been approving biosimilars
for over a decade, the first approved in 2006. In contrast, the first FDAapproved biosimilar was in 2015.194 The EMA approval dates also show
that the EMA approves more biosimilars every year.195 The FDA is also
increasing its approval rate, though with only three years’ worth of
data—and pending patent litigation and comments on the FDA’s
released interchangeability guidance document—it is difficult to
determine if this approval trend will continue.196
Table 2: Biosimilar Approval Dates in the EMA v. FDA
Active
Substance

adalimumab

bevacizumab

Brand
Name197

Biosimilar
Name

EMA
Approved198

FDA
Approved199

Amgevita

Mar-2017

Sep-2016

Cyltezo

Nov-2017

Aug-2017

Halimatoz

Jul-2018

-

Hefiya

Jul-2018

-

Hulio

Sep-2018

-

Hyrimoz

Jul-2018

Oct-2018

Imraldi

Aug-2017

-

Solymbic

Mar-2017

-

Avastin®

Mvasi

Jan-2018

Sep-2017

Lovenox®

Inhixa

Sep-2016

-

Humira®

LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189 with BIOSIMILAR PRODUCT
INFORMATION, supra note 182.
194. Sandoz’s Zarxio is the first biosimilar to be approved and commercialized in the U.S.
See Siegel & Royzman, supra note 184 and BIOSIMILAR PRODUCT INFORMATION, supra note
182.
195. One in 2006, five in 2007, two in 2008, two in 2009, one in 2010, four in 2013, three
in 2014, four in 2016, sixteen in 2017, and fifteen in 2018. See supra Table 2.
196. Five of nine biosimilars approved in the U.S. were approved in 2017. See infra Table
2.
197. To identify brand name from active substance, see Drugs A-Z List, RXLIST,
https://www.rxlist.com/drugs/alpha_a.htm (last visited Nov. 3, 2018).
198. LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189.
199. BIOSIMILAR PRODUCT INFORMATION, supra note 182.
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Active
Substance

Brand
Name197

enoxaparin
sodium

epoetin alfa

etanercept

filgrastim

follitropin alfa

infliximab

insulin
glargine

Epogen®

Enbrel®

Neupogen®

Gonal-f®

Remicade®

Lantus®

[Vol:59

Biosimilar
Name

EMA
Approved198

FDA
Approved199

Thorinane

Sep-2016

-

Abseamed

Aug-2007

-

Binocrit

Aug-2007

-

Epoetin
Alfa Hexal

Aug-2007

-

Retacrit

Dec-2007

May-2018

Silapo

Dec-2007

-

Benepali

Jan-2016

-

Erelzi

Jun-2017

Aug-2016

Accofil

Sep-2014

-

Filgrastim
Hexal

Feb-2009

-

Grastofil

Oct-2013

-

Nivestim

Jun-2010

Jul-2018

Ratiograsti
m

Sep-2008

-

Tevagrasti
m

Sep-2008

-

Zarzio

Feb-2009

Mar-2015

Bemfola

Mar-2014

-

Ovaleap

Sep-2013

-

Flixabi

May-2016

-

Inflectra

Sep-2013

Apr-2016

Ixifi

-

Dec-2017

Remsima

Sep-2013

-

Renflexis

-

May-2017

Zessly

May-2018

-

Abasaglar
(previously
Abasria)

Sep-2014

-

2019]
Active
Substance

insulin lispro

pegfilgrastim

rituximab
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Brand
Name197

Humalog®

Heulasta®

Rituxan®

somatropin

Norditropin®

teriparatide

Forteo®

trastuzumab

Herceptin®
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Biosimilar
Name

EMA
Approved198

FDA
Approved199

Lusduna

Jan-2017

-

Semglee

Mar-2018

-

Insulin
lispro
Sanofi

Jul-2017

-

Fulphila

Nov-2018

Jun-2018

Pelgraz

Sep-2018

-

Pelmeg

Nov-2018

-

Udenyca

Sep-2018

Nov-2018

Ziextenzo

Sep-2018

-

Blitzima

Jul-2017

-

Ritemvia

Jul-2017

-

Rituzena
(previously
Tuxella)

Jul-2017

Rixathon

Jun-2017

-

Riximyo

Jun-2017

-

Truxima

Feb-2017

Nov-2018

Omnitrope

Apr-2006

-

Movymia

Jan-2017

-

Terrosa

Jan-2017

-

Herzuma

Feb-2018

Dec-2018

Kanjinti

May-2018

-

Ogivri

-

Dec-2017

Ontruzant

Nov-2017

-

Trazimera

Jul-2018

-

-
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IV. AN ANALYSIS OF WHAT IS SLOWING THE UNITED STATES DOWN
Of note, all currently approved biosimilars in the EU have approved
reference biologics that are approved in the US.200 Since the reference
product has already been approved, the issue is not the safety and
efficacy profile of the biologic itself. There is a delay in US approval of
biosimilars, even though the reference products are long-established.
The discrepancies between the number of biosimilars approved by the
FDA versus by the EMA can be explained in a few ways.
A. Differences Between the EMA and FDA Biosimilar Approval
Pathways
First, the EMA has a few more years of experience approving
biosimilars, as their abbreviated pathway has been in place since 2005.201
Though the EMA is more seasoned in the biosimilar field, their methods
of review do not differ much from that of the FDA.202 Furthermore, the
FDA on average has a shorter review time for marketing authorization
than the EMA.203 Additionally, biosimilars should have a lower rigor of
review than original BLAs because they can ride on the coattails of the
reference product’s safety and efficacy data. Therefore, the delay is not
due to protracted FDA review timelines.
For the Center for Biologics Evaluation and Research (“CBER”),204
the only area of focused review is manufacturing practices, product
quality, and interchangeability. Herein lies one difference between the
EU and US biosimilar approval process: the FDA pathway offers a
regulatory designation for interchangeability.205 The EMA, essentially
a network of the regulatory bodies of its Member States, allows

200. Reference biologics can be looked up by brand name on the FDA website. See U.S.
FDA,
DRUGS@FDA:
FDA
APPROVED
DRUG
PRODUCTS,
https://www.accessdata.fda.gov/scripts/cder/daf/.
201. Schiestl et al., supra note 124.
202. Id. Europe, the USA, and Japan adhere to the International Conference on
Harmonization Q5E tripartite comparability guidelines. See EUROPEAN MED. AGENCY, ICH
TOPIC Q5E: COMPARABILITY OF BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS, (June 2005),
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC
500002805.pdf (which outlines considerations for comparability exercises, quality,
manufacturing process, comparability during development, and nonclinical and clinical
studies).
203. Norman, supra note 42.
204. The Center for Biologics Evaluation and Research (CBER) “ensure[s] the safety,
purity, potency, and effectiveness of biological products including vaccines, blood and blood
products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of
human diseases, conditions, or injury.” U.S. FDA, CBER VISION & MISSION,
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBE
R/ucm122878.htm.
205. 42 U.S.C. § 262(k)(4)(B).
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individual members to adopt the heightened interchangeability
requirement at the national level.206
Pursuing interchangeability may be worth adding a transition study,
but an additional study does increase the approval timelines.
Interchangeability standards are clearer compared to formulary rules for
switching patients to “highly similar” biosimilars.207 Theoretically, this
means that the United States has a longer process for biosimilar
regulatory approval if there is an incentive to pursue interchangeability
before approval to engender trust by patients and clinicians for
substitution. In comparison, the heightened interchangeability
requirement is incidental in the EMA.208 EU Member States individually
regulate interchangeability, switching, and substitution.209 Of course,
information from scientific evaluation performed by EMA’s scientific
committees can be used to support decisions.210 Nevertheless, the
member-state level approval does not affect EMA biosimilar approval.
The impact is downstream, after a biosimilar is already approved. The
impact is at the prescription and pharmacy-level, where each memberstate has regulations on how a biosimilar may be used and its insurance
reimbursement scheme.211
B. Unfamiliarity with Biosimilars
Despite the licensure pathway for biosimilars in the US, the
biosimilar approvals may be slow because of the lack of statutory
guidance, the higher hurdles of entry as compared to generic products,
and a general lack of familiarity with biosimilar products.212 Surveyed
US health care professions expressed safety concerns and the need for
more evidence before considering biosimilars as acceptable
alternatives.213 Since FDA biosimilar approval is based on molecular
similarity, the lessened emphasis on clinical evidence from randomized
206. Schiestl et al., supra note 124.
207. See Stephen Barlas, FDA Guidance on Biosimilar Interchangeability Elicits Diverse
Views, 42 PHARMACY & THERAPEUTICS 509 (2017).
208. EUROPEAN MED. AGENCY, BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR
HEALTHCARE PROFESSIONALS 29,
http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.p
df (last visited Jan. 30, 2018).
209. Id.
210. Id.
211. Evelien Moorkens et al., Policies for Biosimilar Uptake in Europe: An Overview,
PLOS ONE (Dec. 28, 2017),
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190147.
212. Ralph Boccia et al., Can Biosimilars Help Achieve the Goals of US Health Care
Reform?, 9 CANCER MGMT. & RES. 197 (June 1, 2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459961/.
213. Id.
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trials raises concerns about immunologic effects, especially if a
prescriber were to switch a patient from the standard of care to a
biosimilar.214 Approved interchangeable products could alleviate these
concerns. However, no biosimilar has yet been designated as
interchangeable in the US.215
C. Patent Rights Affecting Approval Timelines
Patent litigation could also be slowing down the FDA process.
Companies can market approved biosimilars after the reference
medicine market protection expires after about ten years.216 As of 2017,
thirty-seven biosimilars are approved by the EMA. In the US,
biosimilars will not be approved until twelve years after the date a
reference product was first licensed.217
In 2015, the Supreme Court by unanimous decision in Sandoz v.
Amgen paved the way for the first biosimilar approval in the US.218
Sandoz produced Zarxio (filgrastim) with the intention of marketing
Zarxio with Amgen’s Neupogen as the reference product, in accordance
to the BPCIA.219 The FDA accepted Sandoz’s application for review.
Sandoz then gave notice to Amgen of its intent to market Zarxio
immediately upon FDA approval.220 Blindsided, Amgen sued Sandoz
for violations of the BPCIA, which included Sandoz’s failure to provide
notice of commercial marketing under § 262(l)(8)(A) prior to obtaining
licensure from the FDA.221 “Section 262(l) (8)(A) contains a single
timing requirement: The applicant must provide notice at least 180 days
prior to marketing its biosimilar.”222 There is no reference in the
applicable statute to a notification timing requirement prior to FDA
licensure. By not creating an artificial marketing delay for approved
biosimilars, the Court created a profit motive for biosimilar marketers.
In theory, Sandoz should expedite the timelines for biosimilars to hit the
market, but the effects remain yet to be seen.

214. Id.
215. Joshua Cohen, What’s Holding Back Market Uptake of Biosimilars?, FORBES, June
29, 2018, https://www.forbes.com/sites/joshuacohen/2018/06/20/whats-holding-backmarket-uptake-of-biosimilars/#12f060f9691a.
216. EUROPEAN MED. AGENCY, BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR
HEALTHCARE PROFESSIONALS 28 (2017),
https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcareprofessionals_en.pdf.
217. 42 U.S.C. § 262(k)(7)(A).
218. See Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664 (2017).
219. Id. at 1666.
220. Id.
221. Id. at 1667.
222. Id. at 1677.
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Notably, like the EU regulatory scheme, the BPCIA does not allow
a sponsor to renew data exclusivity due to changes in drug strength,
formulation, or route of administration.223 This is to prevent arbitrary
formulary changes that act as a pretext for extending the data exclusivity
period. However, the BPCIA does allow for “second-generation
biological product with structural modifications” that changes the safety,
purity, or potency of the original product.224 Such restrictions on a
sponsor’s data exclusivity should promote biosimilars approval.
D. A Case Study: The FDA Rejects Pfizer’s Epoetin Biosimilar
Epoetin alfa is an injectable drug that treats anemia associated with
chronic kidney failure, including patients that are receiving dialysis.225
It works by stimulating the bone marrow to produce red blood cells. It
is a treatment, not a cure, and is used indefinitely.226
In an FDA Briefing Document posted May 25, 2017 prior to an
advisory committee meeting, FDA reviewers lauded Pfizer’s epoetin
alfa biosimilar “Epoetin Hospira” as being “highly similar” to Amgen’s
Epogen based on the totality of analytical data.227 Surprisingly, despite
the endorsement from the FDA staff and an advisory committee, Pfizer’s
biosimilar for Amgen’s Epogen was rejected a second time.228 The crux
of the issue was a fill-finish plant that was acquired by Pfizer with their
acquisition of Hospira. 229 The BLA listed this plant as a potential
manufacturing site for the proposed biosimilar,230 although it was subject
to four warning letters in a four year period.231 Other manufacturing sites
within the same network were cited for CGMP violations too.232 This
223. Gitter, supra note 165, at 591.
224. Id.
225. Omudhome Ogbru, Epoetin Alfa, MEDICINENET.COM,
https://www.medicinenet.com/epoetin_alfa/article.htm#what_is_the_dosage_for_epoetin_alf
a? (last visited Jan. 30, 2018).
226. Id.
227. U.S. FDA, FDA BRIEFING DOCUMENT, ONCOLOGIC DRUGS ADVISORY COMMITTEE
MEETING, BLA 125545 “EPOETIN HOSPIRA,” A PROPOSED BIOSIMILAR TO EPOGEN/PROCRIT
(EPOETIN ALFA) (May 25, 2017),
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
OncologicDrugsAdvisoryCommittee/UCM559967.pdf.
228. Eric Palmer, FDA Rejects Pfizer’s Epogen Biosimilar for the Second Time,
FIERCEPHARMA (June 22, 2017), https://www.fiercepharma.com/regulatory/fda-rejectspfizer-s-epogen-biosimilar-for-a-second-time.
229. Id.
230. Press Release, Pfizer, Pfizer Provides Update on Proposed Epoetin Alfa Biosimilar
(June 22, 2017), https://investors.pfizer.com/investor-news/press-release-details/2017/PfizerProvides-Update-on-Proposed-Epoetin-Alfa-Biosimilar/default.aspx.
231. Palmer, supra note 228.
232. Andrew D. Cohen, The Travails of the First U.S. EPO Biosimilar, BIOLOGICS BLOG
(July 10, 2017), https://www.biologicsblog.com/the-travails-of-the-first-u-s-epo-biosimilar.
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unexpected rejection is expected to delay Epoetin Hospira through
2018.233 In contrast, Binocrit, the first epoetin alfa biosimilar, was
approved by the EMA in 2007, over ten years ago.234
Since Binocrit was approved over a decade ago, it does not seem
that there are misgivings about the safety and efficacy of the product
itself. The variable affecting its rejection was manufacturing practices
that were not compliant with relevant regulation. This surprising
rejection illustrates that manufacturing fidelity is a key component to
biosimilar approval. Now, with the US mutually recognizing EUapproved manufacturing sites as compliant, perhaps there is a way for
the US to accept the biosimilars that are produced at those sites.
V. EU-APPROVED BIOSIMILARS COULD PAVE THE WAY FOR
APPROVALS IN THE UNITED STATES
A. Mutual Recognition of Manufacturing Inspections Does Make
Mutual Recognition of Biosimilars Feasible
One justification for the 2017 Amendment to the US-EU MRA was
to better allocate resources for the benefit of patient safety and public
health.235 The MRA aimed to reduce duplicative work while still
recognizing the FDA and EU’s regulatory autonomy by keeping the door
open to inspections as needed.236
The FDA could easily take advantage of this new efficiency. In the
case of epoetin alpha above, the FDA could grant access to epoetin alfa
biosimilars already approved in the EMA. Given that the bottleneck of
the biosimilar approval process is manufacturing assurances, accepting
existing data from the EMA will expedite the FDA review process.
Biosimilars that reference a biologic that has been on the market for a
long time should face no obstacle in terms of patent rights. Furthermore,
biosimilars that have been on the European market for years should have
fewer quality, efficacy, and safety concerns because it has the benefit of
post-market monitoring.237 If the MRA could be applied to biosimilar
review and approval, the US would be a step closer to a more
competitive and affordable biologics market.

233. Id.
234. LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189.
235. FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166.
236. Id.
237. As discussed in supra Part II.E, post-market drug use by a larger patient population
will yield aggregate epidemiological data that may not have been observed during a clinical
trial’s limited time period and scope.

2019]

MUTUAL RECOGNITION OF BIOSIMILARS

233

B. Some Countries Already Mutually Recognize Third-Party Data for
Assessment Purposes…
Mutual recognition of assessment and inspection results is not a
novel concept. There are non-EU regulatory authorities that base their
market approvals on EU assessments.238 Switzerland, for example, will
make a medicinal product already authorized in another country readily
available to its patient population as rapidly as possible.239 This has
reduced new product review time by up to twenty percent.240 This
example highlights a generous application of the mutual recognition
doctrine. Admittedly, Switzerland’s deference to a mutual recognition
regulatory standard is colored by Switzerland’s special relationship with
the EU. Like EU-member countries, the Swiss-EU relationship is
motivated by economic protectionism.241 The US does not have such a
relationship with the EU. Thus, a mutual recognition model like
Switzerland’s is too deferential to EMA authority to be a possibility in
the US.
Perhaps a more conservative model is the International Generic
Drug Regulators Programme (“IGDRP”),242 which launched an
information-sharing pilot in 2014 to enable mutual recognition of
generic drugs across participating countries.243 In addition to the EU
authorities, participants include regulatory authorities for Canada
(Health Canada), Switzerland (Swissmedic), Taiwan (Taiwan Food and
Drug Administration), and Australia (Therapeutic Goods
Administration).244 IGDRP utilized the EU decentralized procedure to
model their initiative.245 As discussed above, under the decentralized
procedure Member States adopt mutual recognition of medicines that
have not previously received marketing authorization by relying on the
national authorization granted by one Member State.246 Here, the
participating members agreed to converge their regulatory standards so
that drugs approved in one participating country has a pathway for
238. Luigetti et al., supra note 104, at 562.
239. Id. at 563.
240. Id.
241. Switzerland’s economic and trade relations with the EU are governed through a series
of bilateral agreements, which grants Switzerland access to the EU’s single market. The EU
is Switzerland’s main trading partner. See EUROPEAN COMM’N, COUNTRIES AND REGIONS:
SWITZERLAND, http://ec.europa.eu/trade/policy/countries-and-regions/countries/switzerland/
(last updated Apr. 16, 2018).
242. International Generic Drug Regulators Programme was launched to increase
efficiency in generic drug review.
243. Luigetti et al., supra note 104, at 561.
244. Id.
245. Directive 2004/27/EC outlines the decentralized procedure for marketing
authorization. See Directive 2004/27/EC, O.J. (L 136/44), art. 24.
246. Procedure discussed supra Part II.B.3.
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authorization in another country without duplicating effort.247 The
program stated that promoting generic drug availability was a goal, even
though the program excluded biosimilars.248 However, because
biosimilars are analogous to generics—they are reproductions of an
approved reference product with an established safety and efficacy
record—recognition of biosimilars among IGDRP participants could
follow the same procedure. Likewise, the US could also participate in
such a program. However, because the FDA was founded upon
consumer protection principles (as opposed to the EMA’s economic
protection principles),249 basing approvals off other countries’
evaluations sacrifices too much regulatory authority. This is a huge
jump from merely accepting multinational data as a supplement to an
approval.
The FDA will use, where appropriate, foreign reviews to
supplement its evaluation of a product for market authorization.250 As
clinical research is becoming increasingly global the FDA recognizes
that sponsors may conduct multinational clinical studies.251 When the
foreign clinical study is not conducted under an IND, the sponsor must
ensure that the study complies with the requirements in 21 C.F.R. §
312.120252 for the data to qualify for marketing approval.253 The study
must produce data that can be validated by the FDA and study sites must
be open to onsite inspection if necessary.254

247. Mike Ward, Regulatory Harmonization, 28 WHO DRUG INFO. 3, 5-6 (2014),
http://www.who.int/medicines/publications/druginformation/DI_28-1_RegulatoryHarmonization.pdf.
248. Id. at 6.
249. Historically, the FDA was empowered by consumer-protection concerns, as
discussed supra Part II.A. The EMA, as the EU’s regulatory agency, promotes an EU’s
principle to achieve market efficiency via a single market. See EUROPEAN MED. AGENCY,
FACT SHEETS ON THE EUROPEAN UNION: MEDICINES AND MEDICAL DEVICES,
http://www.europarl.europa.eu/factsheets/en/sheet/46/consumer-policy-principles-andinstruments.
250. Luigetti et al., supra note 104, at 563.
251. U.S. FDA, GUIDANCE FOR INDUSTRY AND FDA STAFF: FDA ACCEPTANCE OF
FOREIGN CLINICAL STUDIES NOT CONDUCTED UNDER AN IND FREQUENTLY ASKED
QUESTIONS 2 (Mar. 2012),
https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM294729.pdf.
252. 21 C.F.R. § 312.120 governs foreign clinical studies not conducted under an IND.
Under this section, studies are acceptable if they were conducted in compliance with good
clinical practice, which is also defined in the section. The produced data must also be able to
be validated by the FDA.
253. 21 C.F.R. § 312.120.
254. Id.
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C. …But the FDA Indicates that Interchangeability Comparators
Should be US-Approved
Accepting multinational clinical data as a supplement to a
marketing approval application still allows the FDA to retain regulatory
autonomy. The FDA could also accept supplemental clinical data for
proposed biosimilars. In comparison, the EMA accepts data for
biosimilars that were compared with foreign-approved biologics as long
as there are bridging studies that compare the foreign-approved biologic
with the locally licensed version.255 To an extent, the FDA will accept
comparison study data for highly similar biologics, but the FDA stops
short of allowing foreign comparator products to be used to demonstrate
interchangeability.256
As discussed above, interchangeability is
effectively mandatory in the US market.257
In January 2017, the FDA published the long-awaited draft
guidance for industry titled “Considerations in Demonstrating
Interchangeability With a Reference Product.”258 Of note, the draft
guidance document states that a non-US-licensed comparator may be
used for purposes of demonstrating biosimilarity, but “using a non-USlicensed comparator product generally would not be appropriate” in a
switching study supporting a determination of interchangeability. 259
Switching studies are designed to assess whether switching between a
comparator and the proposed biosimilar will affect the immune system’s
response once the switch occurs.260 A non-US-licensed comparator
product could have subtle differences with a US-licensed comparator
product.261 Results from a switching study using a non-US-licensed
comparator product would lead to uncertainty about the cause of any
immunologic responses.262
However, the US-licensed comparator requirement does not detract
from the US-EU MRA’s potential to give EU-approved biosimilars a
pathway for US approval, even under heightened interchangeability
255. Christopher J. Webster & Gillian R. Woollett, A ‘Global Reference’ Comparator for
Biosimilar
Development,
31
BIODRUGS
279,
279
(May
19,
2017),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541093/pdf/40259_2017_Article_227.pdf.
256. Id.
257. See supra note 148 and accompanying text. Biosimilars can only be substituted for
a prescribed biologic if it is interchangeable. See BIOSIMILAR AND INTERCHANGEABLE
PRODUCTS, supra note 130.
258. U.S. FDA, DRAFT GUIDANCE FOR INDUSTRY: CONSIDERATIONS IN
DEMONSTRATING INTERCHANGEABILITY WITH A REFERENCE PRODUCT (Jan. 2017),
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan
ces/UCM537135.pdf.
259. Id. at 15.
260. Id.
261. Id.
262. Id.
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requirements. All the EMA-approved biosimilars have US-approved
biologic reference products.263 EMA-approved biosimilars that were
approved based on comparator studies with a US-approved biologic
reference product can still qualify under the FDA draft guidance. In that
scenario, switching studies meeting the FDA criteria have already been
completed, albeit in another country.
D. Complete Mutual Recognition of Approved Products is Likely Not
Realistic…
Complete mutual recognition of approved products has been
proposed as clinical development of novel therapies become
increasingly globalized. However, the legal frameworks of each
Member State of the EMA and the FDA are too much to untangle
anytime soon.264 The healthcare systems are so vastly different, meaning
that there are differing levels of motivations to use biosimilars as a
medicine price control scheme. The EU, with a more socialized
healthcare approach, is incentivized to drive down the costs of
therapeutic products, sometimes by implementing government-set prices
in order to achieve that objective.265 For the US, the BPCIA as part of
the Affordable Care Act is slowly driving the US towards approving
more biosimilars. But the biosimilar approval pathway shows a uniquely
American concern for patent rights: developers are granted twelve years
of market exclusivity for new biologics, but future access to these high
cost drugs is encouraged by allowing entrants to compete after
exclusivity and patent expiration.266
Ultimately, the discrepancy in the approach to biosimilars is
because the FDA and EMA were founded on different principles. The
FDA originated as a consumer protection agency.267 The EMA was born
from the EU as a market protection initiative.268 Different origin stories
do inform their respective openness to mutual recognition procedures:
the FDA has a tradition of autonomy and a long-history of increasingly
discerning scientific standards, which could mean that it is wary of
trusting other agencies, even the EMA, to do its work. In contrast, the
EMA has a tradition of fostering collaboration amongst its country
263. See supra Part III.A, Table 2.
264. Luigetti et al., supra note 104, at 565.
265. Carmen Paun, Europe’s Health Systems on Life Support, POLITICO,
https://www.politico.eu/article/europe-health-care-systems-on-life-support-special-reportdrug-pricing-medicines-public-services/ (last updated Oct. 7, 2016).
266. Joseph P. Fuhr et al., Product Naming, Pricing, and Market Uptake of Biosimilars,
4 GENERICS & BIOSIMILARS INITIATIVE J. 64 (2015).
267. See supra Part II.
268. See supra Part II.C.
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participants, meaning it was built on mutual recognition procedures
between Member States of the EU and other countries in the European
Economic Area.
E. …But Biosimilars are a Good Start towards International
Harmonization
Variation in the biologics manufacturing processes exist for reasons
such as “scaling up of the process, improving efficiency, or
modernization when equipment needs to be updated or replaced.”269 “To
allow such manufacturing changes to occur without the need for
companies to conduct a new clinical development program, regulators
devised the comparability concept to establish whether the pre- and
postchange [sic] products were sufficiently similar to permit ongoing
marketing under the same product label.”270 As such, with the step that
the FDA and EMA have now taken to align their manufacturing
standards, any misgivings that the FDA may have to an EMA-approved
biosimilar can be resolved via the comparability scheme.
A change to the manufacturing process must always be approved
by regulators. Analytical and functional data is usually sufficient for
continued approval of the biosimilar. In rare cases, additional clinical
studies need be done to demonstrate no impact on quality, safety, and
efficacy.271 Here, it logically follows that the FDA could move towards
developing a means to grant authorization to a requesting manufacturer
that is already producing an EMA-approved biosimilar. Any concerns
about the safety and efficacy of the EMA-approved biosimilar can be
addressed by invoking the right to conduct supplementary inspections, a
right reserved in the 2017 Amended US-EU MRA.
VI. CONCLUSION
Instead of being years behind, the United States’ biosimilars
initiative could be ramped up so that the market for biosimilars in the
United States is comparable to the European Union’s. The FDA
releasing a formal guidance on interchangeability requirements certainly
will clear some regulatory uncertainty in the US. Additionally, the
Mutual Recognition Agreement for manufacturing inspections presents
a great opportunity for the FDA to approve a wider range of biosimilars
whose manufacturing practices are deemed compliant by the EU. After
the United States validates EU manufacturing sites on a national

269. Schiestl et al., supra note 124.
270. Id.
271. Id.
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member-state level, the US could approve biosimilars produced at those
approved sites.
The next step is for the FDA to build upon the agreement and work
towards recognizing that the biosimilars that are manufactured under
robust EMA guidelines are fit for approval in the United States too. By
approving more biosimilars in the US, competition increases in the
biologics market, which will drive down drug costs, which is analogous
to the effect that generic product availability has on drug pricing. This
is important because biologics are prone to price markup. Unlike
traditional drugs, biologics are genetically engineered from cell cultures,
which do make them costlier to produce. Additionally, biologics are
typically delivered intravenously or subcutaneously.272 “[T]he markup
of an infused medicine is greater in an inpatient setting than in a
physician office, providing an incentive for institutions able to
administer drugs in a setting that qualifies as inpatient.” 273
Of course, there are misgivings from the private sector, as
demonstrated by the current biosimilar litigation landscape, but existing
patent-exclusivity periods exist to remedy those concerns. Admittedly,
the outcome of patent litigation over manufacturing techniques could
greatly affect biosimilar survival to market.274 Nevertheless, muchneeded, long-established therapies should not be held hostage to a
bureaucratically drawn-out approval process.
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